H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $15 from $19 and keeps a Buy rating on the shares following the Q4 report. The firm cites the impact of increased projected operating expenses on the stock’s valuation for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
- Promising Efficacy of Alumis Inc.’s ESK-001 in Psoriasis Treatment Boosts Market Position and Buy Rating
- Alumis announces data from the OLE of its Phase 2 STRIDE trial
- Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating
- Alumis Inc. Announces Merger with ACELYRIN, Inc.
- Acelyrin says Concentra indication not expected to result in superior proposal